Company: ARTL
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001640334-25-001429
Chunk: 388

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 388
---
 of Stockholders’ (Deficit) Equity

(Unaudited)

(In thousands)

     Additional     Accumulated Other       Common stock  Paid-in  Accumulated  Comprehensive      Shares  Amount  Capital  Deficit  Income (loss)  Total                    Balance, December 31, 2024  567  $1  $53,194  $(50,136) $(202) $2,857                          Common shares issued for cash  -   -   -   -   -   - Stock based compensation  -   -   192   -   -   192 Net loss for the period  -   -   -   (2,372)  -   (2,372)Other comprehensive loss  -   -   -   -   (25)  (25)Balance, March 31, 2025  567  $1  $53,386  $(52,508) $(227) $652                          Common shares issued for cash, net of issuance costs  137   -   1,081   -   -   1,081 Stock based compensation  -   -   150   -   -   150 Net loss for the period  -   -   -   (3,221)  -   (3,221)Other comprehensive loss  -   -   -   -   (68)  (68)Balance, June 30, 2025  704  $1  $54,617  $(55,729) $(295) $(1,406)

     Additional     Accumulated Other       Common stock  Paid-in  Accumulated  Comprehensive      Shares  Amount  Capital  Deficit  Income (loss)  Total                    Balance, December 31, 2023  532  $1  $52,264  $(40,310) $(203) $11,752                          Common shares issued for cash  6